10-K: Nexalin Technology Reports Full Year 2023 Results, Focuses on Next-Gen Device Development and Regulatory Approvals

Nexalin Technology's 2023 annual report highlights a shift towards next-generation device development and regulatory approvals, with a focus on new clinical trials and a virtual clinic model.

Summary

• Nexalin Technology reported a comprehensive loss of $4,685,427 for the year ended December 31, 2023, and an accumulated deficit of $77,038,049.
• The company is focusing on developing its Generation 2 (Gen-2) and Generation 3 (Gen-3) devices, which utilize a 15 milliamp waveform, and is planning clinical trials for various mental health conditions.
• Revenue decreased significantly to $110,748 in 2023 from $1,321,357 in 2022, primarily due to the suspension of new Gen-1 device sales and a downturn in the Chinese market.
• Operating expenses increased to $5,781,356 in 2023, driven by higher salaries, research and development costs, and stock-based compensation.
• The company formalized a joint venture in China to develop and market its Gen-2 devices, with Wider Come Limited funding initial operations.
• Nexalin is developing a virtual clinic model to address the stigma associated with mental health treatment, which will include a Gen-3 headset for home use.
• The company is pursuing regulatory approvals for its Gen-2 and Gen-3 devices in the U.S. and China, including a new PMA application for depression treatment.
• The company is planning pilot and pivotal trials for anxiety and insomnia in the U.S. and China, with data collection expected to take approximately 18 months.
• The company is also exploring the use of its technology for substance use disorders, chronic pain, Alzheimers disease, and dementia.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in terms of technology and strategic direction, the significant financial losses, decreased revenue, and the need for additional funding raise concerns. The company is also facing regulatory hurdles and competition, which adds to the uncertainty.

Positives

• The company is developing a new virtual clinic model to address the stigma associated with mental health treatment.
• The company has a proprietary design that stabilizes currents, electromagnetic fields, and various frequencies, particularly its 15 milliamp patented symmetrical waveform.
• The company has a joint venture in China to develop and market its Gen-2 devices.
• The company is exploring the use of its technology for substance use disorders, chronic pain, Alzheimers disease, and dementia.
• The company has completed 2 prototypes of a Nexalin headset which can be used at home or in a clinical setting.

Negatives

• The company reported a significant comprehensive loss of $4,685,427 for the year ended December 31, 2023.
• Revenue decreased significantly to $110,748 in 2023 from $1,321,357 in 2022.
• Operating expenses increased to $5,781,356 in 2023.
• The company has a significant accumulated deficit of $77,038,049.
• The company has suspended marketing efforts for new sales of devices related to the Gen-1 device for treatment of anxiety and insomnia in the United States.

Risks

• The company has incurred significant losses since its inception and may never achieve or maintain profitability.
• The company may require additional funding to meet its financial needs and to pursue its business objectives.
• The company depends on the success of its future products, some of which are in clinical development but have not completed advanced clinical trials.
• The company relies on third parties to conduct clinical trials and for quality assurance of its products.
• The company may not be able to obtain regulatory approval for its products or achieve market acceptance.
• The company faces competition from other companies and organizations that are marketing or developing therapies for its targeted disease indications.
• The company is subject to the risks of conducting business internationally, particularly in China.
• The company may be subject to anti-monopoly concerns as a result of doing business in China.
• The company may be subject to regulatory and other risks if it were to operate Variable Interest Entities in China.
• The company may not be able to obtain and maintain patent protection for its technologies and products.
• The company may become involved in lawsuits to protect or enforce its patents or other intellectual property.
• The company may be subject to product liability lawsuits.
• The company may not be able to retain key executives and to attract, retain and motivate qualified personnel.
• The company may encounter difficulties in managing its growth.
• The company may experience significant disruptions of its information technology systems or data security incidents.
• The company may be subject to the U.S. Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws.
• The company may be subject to the U.S. and foreign export controls, trade sanctions and import laws and regulations.
• The company may not be able to maintain its listing on the Nasdaq Stock Market.
• The trading price of the company's common stock and warrants may be volatile.
• The company may be subject to anti-monopoly concerns as a result of doing business in China.

Future Outlook

The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S. and has consulted the FDA as part of the pre-submission meetings. The company is also planning pilot and pivotal trials for anxiety and insomnia in the U.S. and China, with data collection expected to take approximately 18 months. The company is also exploring the use of its technology for substance use disorders, chronic pain, Alzheimers disease, and dementia.

Management Comments

• The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3 devices can penetrate deeper into the brain and stimulate associated structures of mental illness, which we believe will generate enhanced patient response without any risk or unpleasant side effects.
• Our research and clinical teams believe that a more powerful waveform will create a stronger response in the brain.
• A stronger response creates a higher level of efficacy.
• This entire proprietary technique allows Nexalin to provide a non-invasive and comfortable treatment that is more powerful than any stimulation device in the market.
• Our mission is to remove the stigma of expensive psychotherapy or pharmaceuticals with the attendant side effects and dependency issues and replace it with clinically proven and cost-effective technology that is easily accessible in the privacy of the patients home and monitored by licensed healthcare providers.

Industry Context

The document highlights the growing global mental health epidemic and the need for innovative, non-invasive treatments. It positions Nexalin's technology as a potential disruptor in the traditional mental health treatment model, offering a cost-effective and accessible alternative to pharmaceuticals and psychotherapy. The company is also addressing the stigma associated with mental health treatment by developing a virtual clinic model.

Comparison to Industry Standards

• The document mentions that traditional pharmaceutical therapies and neurostimulators have side effects, high costs, and moderate efficacy, which Nexalin aims to address with its technology.
• The company's 15 milliamp waveform is presented as a more powerful and effective alternative to existing stimulation devices.
• The company's virtual clinic model is designed to provide a more accessible and convenient treatment option compared to traditional in-person therapy.
• The company is developing a proprietary IT management platform to manage all aspects of the virtual clinic model, which is intended to be more advanced than existing telehealth platforms.
• The company is also developing a proprietary single use electrode with RFID technology to ensure a recurring revenue stream and protect against generic knockoffs.

Management Changes

Legal Proceedings

• The company is involved in a lawsuit filed by Sarah Veltz, alleging unpaid wages and sexual harassment.
• The company is engaged in settlement discussions with the Employment Development Department (EDD) of the State of California regarding employment tax liability.
• The company has settled a demand letter from the University of Arizona for $69,000.

Related Party Transactions

• The company has a consulting agreement with U.S. Asian Consulting Group, LLC, whose members are shareholders and one of whom was the former CFO.
• The company has a sublease agreement with an entity controlled by its Chief Executive Officer.
• The company has a joint venture agreement with Wider Come Limited, a related party.
• The company has a loan payable to its Chief Executive Officer.

Stakeholder Impact

• Shareholders face the risk of losing their investment due to the company's financial losses and need for additional funding.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers may benefit from the company's innovative technology and virtual clinic model.
• Suppliers may be affected by the company's financial challenges and potential changes in its operations.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S.
• The company is planning pilot and pivotal trials for anxiety and insomnia in the U.S. and China.
• The company is developing a new virtual clinic model.
• The company is pursuing regulatory approvals for its Gen-2 and Gen-3 devices in the U.S. and China.
• The company is exploring the use of its technology for substance use disorders, chronic pain, Alzheimers disease, and dementia.

Key Dates

Keywords

neurostimulation, mental health, anxiety, insomnia, depression, FDA, clinical trials, virtual clinic, China, joint venture, regulatory approval, bioelectronic medical technology, waveform technology, substance use disorders, Alzheimers disease, dementia